<DOC>
	<DOCNO>NCT02624869</DOCNO>
	<brief_summary>To describe safety tolerability 80 week subcutaneous ( SC ) evolocumab ( AMG 145 ) add standard care pediatric subject 10 17 year age HeFH HoFH .</brief_summary>
	<brief_title>Open Label Study Evaluate Safety , Tolerability Efficacy Evolocumab ( AMG 145 ) Pediatric Subjects ( 10 17 Years Age ) With Heterozygous Familial Hypercholesterolemia ( HeFH ) Homozygous Familial Hypercholesterolemia ( HoFH ) .</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Subjects HeFH : Completed Study 20120123 still assign investigational product experience treatment‑related serious adverse event Subjects HoFH : Male female , ≥ 10 ≤ 17 year age time enrollment Diagnosis HoFH On lowfat diet receive background lipidlowering therapy Lipidlowering therapy unchanged ≥ 4 week prior LDLC screening ; fibrates must stable least 6 week prior screen . Fasting LDLC screen ≥ 130 mg/dL ( 3.4 mmol/L ) Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) All Subjects Currently receive treatment another investigational device drug study , less 30 day since end treament another investigational device drug study ( ) ; except Study 20120123 Subjects HoFH : Moderate severe renal dysfunction Active liver disease hepatic dysfunction , CK &gt; 3 time ULN screening</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>PCSK9 mutation</keyword>
	<keyword>Severe Familial Hypercholesterolemia</keyword>
	<keyword>evolocumab</keyword>
	<keyword>Repatha</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Paediatric</keyword>
</DOC>